Serum levels of ADAM6 were significantly higher in ALL and AML patients compared to healthy control subjects (208.7(178.3–337.3), 186.4(155.3–479.6), and 78.6(55.8–101.8) pg/ml, p < 0.0001), respectively. This evidence concerns the gene ADAM6 and acute lymphoblastic leukemia.